1. Glioma-on-a-Chip Models
- Author
-
Sajjad Rahmani Dabbagh, Savas Tasoglu, Tugba Bagci-Onder, Irem Sultan Ilci, Merve Ustun, Önder, Tuğba Bağcı (ORCID 0000-0003-3646-2613 & YÖK ID 184359), Taşoğlu, Savaş (ORCID 0000-0003-4604-217X & YÖK ID 291971), Üstün, Merve, Rahmani Dabbagh, Sajjad, İlçi, İrem Sultan, KU Arçelik Research Center for Creative Industries (KUAR) / KU Arçelik Yaratıcı Endüstriler Uygulama ve Araştırma Merkezi (KUAR), Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), School of Medicine, College of Engineering, Graduate School of Sciences and Engineering, Graduate School of Social Sciences and Humanities, Department of Mechanical Engineering, Department of Biomedical Sciences and Engineering, and Department of Design Technology and Society
- Subjects
Drug ,tumor-on-a-chip ,media_common.quotation_subject ,medicine.medical_treatment ,brain ,02 engineering and technology ,Bioinformatics ,Organ-on-a-chip ,03 medical and health sciences ,tissue-on-a-chip ,Glioma ,glioma ,medicine ,TJ1-1570 ,Mechanical engineering and machinery ,Electrical and Electronic Engineering ,Survival rate ,030304 developmental biology ,media_common ,0303 health sciences ,organ-on-a-chip ,business.industry ,Mechanical Engineering ,Cancer ,021001 nanoscience & nanotechnology ,medicine.disease ,Analytical chemistry ,Nanoscience and nanotechnology ,Instruments and instrumentation ,Applied physics ,3. Good health ,Radiation therapy ,Brain ,Tissue-on-a-chip ,Disease-on-a-chip ,Tumor-on-a-chip ,Control and Systems Engineering ,Cancer cell ,Perspective ,disease-on-a-chip ,Personalized medicine ,0210 nano-technology ,business - Abstract
Glioma, as an aggressive type of cancer, accounts for virtually 80% of malignant brain tumors. Despite advances in therapeutic approaches, the long-term survival of glioma patients is poor (it is usually fatal within 12-14 months). Glioma-on-chip platforms, with continuous perfusion, mimic in vivo metabolic functions of cancer cells for analytical purposes. This offers an unprecedented opportunity for understanding the underlying reasons that arise glioma, determining the most effective radiotherapy approach, testing different drug combinations, and screening conceivable side effects of drugs on other organs. Glioma-on-chip technologies can ultimately enhance the efficacy of treatments, promote the survival rate of patients, and pave a path for personalized medicine. In this perspective paper, we briefly review the latest developments of glioma-on-chip technologies, such as therapy applications, drug screening, and cell behavior studies, and discuss the current challenges as well as future research directions in this field., Scientific and Technological Research Council of Turkey (TÜBİTAK) 2232 International Fellowship for Outstanding Researchers Award; European Union (EU); Horizon 2020; Marie Sk?odowska-Curie Individual Fellowship; Royal Academy Newton-Katip Çelebi Transforming Systems Through Partnership Award; Alexander von Humboldt Research Fellowship for Experienced Researchers; Science Academy’s Young Scientist Awards Program (BAGEP); Outstanding Young Scientists Awards (GEBİP); Bilim Kahramanlari Derneği The Young Scientist Award
- Published
- 2021